Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Terminated × adavosertib × Clear all

Phase

Phase 1 6 Phase 2 3 Phase 1/2 1

Status

Completed 2 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 1

Interventions

pembrolizumab 56 Cyclophosphamide 51 Carboplatin 51 Paclitaxel 43 Nivolumab 38 Cisplatin 38 Gemcitabine 36 Dexamethasone 33 Radiotherapy 30 Capecitabine 27 Rituximab 25 Docetaxel 25 fludarabine 24 Bevacizumab 23 venetoclax 21 Cytarabine 20 avelumab 19 atezolizumab 19 Trastuzumab 19 Oxaliplatin 19 fludarabine phosphate 18 Pemetrexed 18 Fluorouracil 18 Cetuximab 18 Azacitidine 18 Albumin-Bound Paclitaxel 18 130-nm albumin-bound paclitaxel 18 aldesleukin 17 Temozolomide 17 Filgrastim 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01076400 2023-09-18

MK-1775-008

Merck Sharp & Dohme LLC

Phase 1/2 Terminated

7 enrolled 6 charts

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡